← Pharmacists CPD
Please be informed that participation in the post-test assessment is mandatory for the issuance of certificates and the allocation of associated CPD points. Completion and passing of the post-test are required to validate your attendance and ensure compliance with CPD accreditation requirements. Thank you for your cooperation and commitment to professional development.
Participation in this training is entirely voluntary, and you are free to opt out at any time. Please be assured that no personal information of any healthcare professional (HCP) will be shared with BI or DP World. Your privacy and confidentiality remain fully protected.
The Ghana CKD Launch – 2025 is a clinician-focused CPD programme designed to translate the latest cardio-renal-metabolic (CRM) evidence into routine practice in Ghana. Through expert-led talks and case-based discussions, participants will examine early detection strategies, guideline-directed medical therapy (GDMT), and the practical integration of SGLT2 inhibitors—anchored by the EMPA-KIDNEY data—across both diabetic and non-diabetic CKD. The hybrid format ensures broad access while maintaining a strong emphasis on practical clinical decision-making, referral pathways, and multidisciplinary coordination between specialist and primary care.
SESSION TOPICS
1. Why early intervention is key to save the kidneys: The role of the Primary Care Physician
-
- Introduce a patient case highlighting CRM disease burden
- Local epidemiology data for CKD and the need for optimising care
- Role of PCPs in early screening, diagnosis, and treatment in CKD
2. Cardio-renal benefits of Empagliflozin in EMPA-KIDNEY: The final piece of the puzzle
-
- Present and interpret the EMPA-KIDNEY trial data
- Position newer therapies within GDMT
- Understand how current guidelines evolved to reflect accumulated evidence
3. Interactive CRM Cases, Panel Discussion & Q&A
-
- Early CKD: “Preserving the kidneys for tomorrow”
- Kidney protection and why RAAS agents alone are not enough in CKD
- Redefining kidney outcomes; SGLT2 inhibitors—guidelines and practice
4. Role of PCPs in Early Screening, Diagnosis, and Treatment
-
- Treatment considerations for CKD with common co-morbidities
- Highlights from international guidance (e.g., KDIGO) and their local application
WHY YOU SHOULD ATTEND/PARTICIPATE
Apply evidence immediately: Turn EMPA-KIDNEY and related CRM evidence into practical, step-by-step care plans.
Strengthen early detection: Sharpen case-finding, risk stratification, and monitoring to slow CKD progression.
Align with guidelines: Confidently implement KDIGO-aligned, GDMT-based algorithms for both T2DM and non-T2DM CKD.
Bridge primary–specialist care: Clarify referral thresholds, shared-care protocols, and follow-up pathways.
Address co-morbidities: Optimise therapy in the context of hypertension, diabetes, dyslipidaemia, and heart failure.
Earn accredited CPD: Obtain recognised credits while building practical tools (checklists, order sets, monitoring plans).
PROUDLY SPONSORED BY
This is a virtual event scheduled for Wednesday the 24th of September, 2025 at 15:00 GMT.
Target Audience: Medical Doctors, Pharmacists
Moderator:
Date: Wednesday, 24th September, 2025
Time: 15:00 GMT (3:00 PM Local Time)
Don’t miss out on this exciting opportunity to elevate your skills and make a lasting impact CRM!
PARTICIPANT CONSENT AND DATA PRIVACY NOTICE
By registering for the “Ghana CKD Launch - 2025”, you consent to participate in this training hosted by CES on behalf of Bohringer Inghelhiem (BI). Your registration will provide us with the necessary information to facilitate the event and issue CPD accreditation through the Medical and Dental Council (MDC), and the Pharmacy Council. Please note that CES is committed to safeguarding your personal information and will not share any personal data with Roche. Your data will only be shared with the relevant regulatory bodies, such as MDC, for the sole purpose of accrediting you with CPD points earned through this training. Additionally, participants are free to opt out of the meeting at any time, and should you wish to do so, no further action is required on your part. We respect your privacy and ensure that your participation will be treated with the highest level of confidentiality.
Overview
Course Description
This hybrid CPD programme equips clinicians to detect CKD earlier and apply guideline-directed therapy across both T2DM and non-T2DM populations, translating cardio-renal-metabolic evidence—especially EMPA-KIDNEY—into practical care. Sessions emphasise the role of primary care in screening and referral, KDIGO-aligned treatment algorithms (including SGLT2 inhibitors), and coordinated specialist–primary workflows. Case-based discussions and panel Q&A focus on risk stratification, medication optimisation, and monitoring plans for common co-morbidities. Participants leave with actionable tools and accredited CPD points.
Participants will begin by exploring the inter-relationship between the heart, kidneys, and metabolic pathways, gaining insights into how dysfunction in one system can drive complications in the others. Building on this foundation, the course will provide practical strategies for diagnosing and identifying CKD in its earliest stages—an essential step in preventing disease progression and reducing long-term complications.
What you will learn
By the end of the programme, participants should be able to:
1.Explain the inter-connection of the cardio-renal-metabolic axis and its implications for CKD progression and outcomes.
2. Implement systematic early-detection workflows (history, labs, eGFR/ACR, risk scoring) in primary and specialist settings.
3. Integrate EMPA-KIDNEY findings into GDMT, selecting and sequencing therapies (including SGLT2 inhibitors) for T2DM and non-T2DM CKD.
4. Operationalise KDIGO-consistent treatment and monitoring plans, including safety checks, dose adjustments, and follow-up intervals.
5. Coordinate multidisciplinary care and referral pathways between PCPs, nephrology, endocrinology, and pharmacy to reduce fragmentation.
6. Customise CKD management in patients with common co-morbidities (HF, HTN, ASCVD, dyslipidaemia), balancing efficacy, safety, and cost.
Course Content
Lecture Sessions
- EVENT DATE: Wed 24th September 2025 @ 1500 GMT (3:00 pm) 2 hours
Downloadables
No downloadable content added to this course yet.
Steps to Join Course
About Facilitators
- 7 Courses on CES
Prof. Vincent Boima
BSc, MBChB, MPH, Cert Nephrology (SA), ISN Fellow, FWACP, FGCP, CaRT Fellow
Senior Lecturer, Head of Nephrology Unit, Consultant Renal Physician.
University of Ghana Medical School and the Department of Medicine and Therapeutics, UGMS, CHS, UG/Korle-Bu Teaching Hospital
Prof. Vincent Boima is an Associate Professor at the University of Ghana Medical School and a Consultant Nephrologist at Korle-Bu Teaching Hospital. He serves as Head of the Department of Medicine and Therapeutics and leads the Renal Unit within the department.
View full profile / courses
- 1 Course on CES
Dr. (Mrs.) Perditer Okyere
MBChB, MPH, FGCP
Head of Nephrology
Komfo Anokye Teaching Hospital, Kumasi
Dr. (Mrs. ) Perditer Okyere is a Senior Lecturer at the School of Medicine and Dentistry, KNUST, and Head of the Nephrology Unit at Komfo Anokye Teaching Hospital.
View full profile / coursesRelated Courses
